Saturday 17 October 2026
Export PBH’s income statement to Excel — free account
Prestige Consumer Healthcare Inc.
PBH Healthcare Drug Manufacturers Specialty & Generic
Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025. In the quarter to June 2026, revenue grew 6.48%, EPS fell 36.5%, free cash flow fell 14.2% and total debt rose 100.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
49.92
0.72
+1.46%
Follow PBH
| Mar '17 | Mar '18 | Mar '19 | Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | Mar '25 | Mar '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 6 | 5 | 9 | 7 | 6 | 6 | 9 | 9 | 5 |
P/E ratio |
42.09 | 5.16 | 0.00 | 13.01 | 13.44 | 12.98 | 0.00 | 17.03 | 19.90 | 15.04 |
Altman Z-Score |
1.17 | 1.21 | 1.09 | 1.43 | 1.67 | 1.87 | 1.85 | 2.64 | 3.06 | 2.48 |
P/S ratio |
3.34 | 1.68 | 1.57 | 1.93 | 2.35 | 2.45 | 2.77 | 3.17 | 3.76 | 2.64 |
Altman Z″-Score (non-manufacturers) |
1.25 | 1.82 | 1.62 | 2.27 | 2.51 | 2.74 | 2.30 | 3.57 | 4.04 | 4.04 |
P/FCF ratio |
20.19 | 8.87 | 8.55 | 9.18 | 10.37 | 10.63 | 14.08 | 14.90 | 17.56 | 11.65 |
Beneish M-Score |
(2.14) | (2.23) | (2.75) | (2.55) | (2.74) | (2.34) | (2.73) | (2.42) | (2.41) | (2.53) |
P/Operating CF |
391.19 | 32.19 | 30.05 | 33.15 | 37.46 | 42.15 | 52.97 | 53.31 | 69.08 | 67.04 |
P/B ratio |
3.58 | 1.49 | 1.39 | 1.59 | 1.63 | 1.69 | 2.16 | 2.15 | 2.33 | 1.52 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
5.79 | 3.57 | 3.39 | 3.64 | 3.90 | 3.79 | 3.92 | 4.14 | 4.57 | 3.52 |
EV/EBITDA |
21.26 | 14.56 | 31.44 | 10.83 | 11.05 | 11.26 | 303.52 | 12.31 | 14.10 | 11.18 |
EV/Operating CF |
34.33 | 17.71 | 17.48 | 16.16 | 15.60 | 15.87 | 19.26 | 18.70 | 20.67 | 14.87 |
EV/FCF |
35.01 | 18.83 | 18.50 | 17.32 | 17.23 | 16.48 | 19.93 | 19.45 | 21.36 | 15.54 |
Quick Ratio |
1.10 | 1.41 | 1.39 | 1.64 | 1.20 | 1.16 | 1.40 | 1.91 | 2.74 | 2.12 |
Current Ratio |
2.06 | 2.46 | 2.37 | 2.44 | 2.21 | 2.04 | 2.44 | 3.20 | 4.20 | 3.57 |
Net Debt/EBITDA |
8.96 | 7.67 | 16.83 | 5.06 | 4.37 | 3.97 | 88.44 | 2.85 | 2.48 | 2.77 |
Debt/Assets |
56.09% | 53.00% | 52.27% | 49.37% | 43.35% | 40.35% | 40.18% | 33.93% | 29.77% | 28.96% |
Debt/Equity |
2.67 | 1.69 | 1.64 | 1.48 | 1.09 | 0.94 | 0.93 | 0.68 | 0.55 | 0.54 |
Asset Turnover |
0.26 | 0.27 | 0.27 | 0.28 | 0.27 | 0.31 | 0.32 | 0.34 | 0.34 | 0.32 |
Operating CF/Net income |
2.14 | 0.62 | (5.29) | 1.53 | 1.43 | 1.27 | (2.79) | 1.19 | 1.17 | 1.35 |
Capex/Depreciation |
(0.08) | (0.31) | (0.28) | (0.44) | (0.63) | (0.27) | (0.21) | (0.27) | (0.26) | (0.34) |
Interest Coverage |
2.20 | 2.03 | 0.64 | 3.03 | 3.61 | 5.13 | (0.32) | 5.10 | 7.07 | 7.31 |
| 8.86% | 33.94% | (3.15%) | 12.55% | 13.02% | 13.99% | (5.44%) | 13.50% | 12.30% | 10.22% | |
| 2.02% | 8.85% | (0.99%) | 4.09% | 4.74% | 5.79% | (2.34%) | 6.28% | 6.39% | 5.52% | |
ROIC |
4.32% | 4.29% | 1.47% | 6.47% | 6.61% | 6.80% | (0.51%) | 7.83% | 7.65% | 6.82% |
Return on Tangible Assets |
31.12% | 145.84% | (15.90%) | 52.36% | 75.63% | 92.87% | (27.30%) | 62.58% | 51.56% | 44.03% |
Average Days of Receivables |
56.58 | 49.39 | 55.66 | 57.05 | 44.37 | 46.79 | 54.06 | 57.34 | 62.33 | 64.34 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
24.66% | 22.35% | 23.86% | 24.54% | 23.71% | 24.37% | 22.38% | 23.06% | 23.20% | 24.36% |
Intangible Assets out of Total Assets |
0.90 | 0.90 | 0.90 | 0.87 | 0.89 | 0.89 | 0.86 | 0.86 | 0.83 | 0.82 |
Share Based Compensation of Revenue |
0.92% | 0.86% | 0.76% | 0.79% | 0.91% | 0.83% | 1.10% | 1.24% | 0.98% | 1.00% |
Graham Net Nets |
(0.94) | (1.30) | (1.34) | (1.06) | (0.81) | (0.68) | (0.48) | (0.36) | (0.26) | (0.41) |
Graham Number |
21.47 | 56.54 | 0.00 | 38.27 | 44.68 | 53.68 | 0.00 | 56.13 | 59.91 | 58.76 |
Earnings Yield |
2.38% | 19.39% | (2.39%) | 7.69% | 7.44% | 7.71% | (2.65%) | 5.87% | 5.03% | 6.65% |
Free Cash Flow Yield |
4.95% | 11.28% | 11.70% | 10.89% | 9.64% | 9.41% | 7.10% | 6.71% | 5.69% | 8.58% |
Revenue per Share |
16.65 | 19.61 | 18.74 | 18.99 | 18.79 | 21.62 | 22.60 | 22.62 | 22.89 | 22.47 |
Operating CF per Share |
2.81 | 3.96 | 3.64 | 4.28 | 4.69 | 5.17 | 4.60 | 5.00 | 5.06 | 5.32 |
Capex per Share |
(0.05) | (0.24) | (0.20) | (0.29) | (0.44) | (0.19) | (0.16) | (0.19) | (0.17) | (0.23) |
Free Cash Flow per Share |
2.75 | 3.72 | 3.43 | 3.99 | 4.25 | 4.98 | 4.45 | 4.81 | 4.90 | 5.09 |
Cash per Share |
0.79 | 0.61 | 0.53 | 1.87 | 0.64 | 0.54 | 1.17 | 0.93 | 1.97 | 1.32 |
Shareholders Equity per Share |
15.53 | 22.20 | 21.05 | 23.09 | 27.05 | 31.39 | 29.01 | 33.26 | 36.92 | 38.95 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
15.53 | 22.20 | 21.05 | 23.09 | 27.05 | 31.39 | 29.01 | 33.26 | 36.92 | 38.95 |
Free Cash Flow |
145.78 | 197.58 | 178.80 | 202.56 | 213.36 | 250.28 | 221.93 | 239.38 | 243.29 | 246.45 |
Working Capital |
172.43 | 180.28 | 173.96 | 215.77 | 147.70 | 149.85 | 231.03 | 258.00 | 341.71 | 310.56 |
Capital Expenditures |
(2.89) | (12.53) | (10.48) | (14.56) | (22.24) | (9.64) | (7.78) | (9.55) | (8.22) | (11.18) |
Net Current Asset Value |
(2,754.36) | (2,278.52) | (2,044.27) | (1,977.28) | (1,801.14) | (1,799.80) | (1,514.90) | (1,288.29) | (1,118.99) | (1,175.31) |
EV/EBIT |
24.82 | 17.27 | 49.00 | 12.05 | 12.36 | 12.50 | 0.00 | 13.60 | 15.43 | 12.38 |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Price to Operating Income |
14.31 | 8.13 | 22.64 | 6.39 | 7.44 | 8.06 | 0.00 | 10.42 | 12.69 | 9.28 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.68 | 0.76 | 0.74 | 0.59 | 0.50 | 0.51 | 0.53 | 0.47 | 0.43 | 0.27 |
Cash ROIC |
4.77% | 6.17% | 6.12% | 6.75% | 7.42% | 8.11% | 7.78% | 8.47% | 8.26% | 8.32% |
Accounts Receivable Turnover |
7.60 | 7.50 | 6.74 | 6.44 | 7.11 | 8.56 | 7.36 | 6.55 | 6.13 | 5.64 |
Accounts Payable Turnover |
7.04 | 7.06 | 7.13 | 6.91 | 7.31 | 9.16 | 8.48 | 9.85 | 17.38 | 23.64 |
Inventory Turnover |
3.69 | 3.97 | 3.52 | 3.48 | 3.43 | 3.96 | 3.56 | 3.33 | 3.51 | 3.21 |
Average Days of Payables |
67.13 | 48.22 | 49.13 | 55.42 | 42.39 | 43.66 | 45.58 | 28.40 | 13.72 | 16.87 |
Days of Inventory on Hand |
110.53 | 93.12 | 104.13 | 103.09 | 105.99 | 94.23 | 117.78 | 101.08 | 107.12 | 117.79 |
Average Receivables |
115.99 | 138.81 | 144.83 | 149.65 | 132.59 | 127.00 | 153.17 | 171.90 | 185.53 | 193.11 |
Average Payables |
54.26 | 65.80 | 58.98 | 59.47 | 54.18 | 50.87 | 59.25 | 50.86 | 28.95 | 20.86 |
Average Inventory |
103.44 | 117.08 | 119.21 | 117.95 | 115.49 | 117.65 | 141.23 | 150.42 | 143.21 | 153.42 |
Average Assets |
3,430.07 | 3,835.98 | 3,600.82 | 3,477.47 | 3,471.59 | 3,549.98 | 3,512.21 | 3,336.07 | 3,360.32 | 3,448.27 |
Average Common Equity |
783.44 | 1,000.58 | 1,137.22 | 1,133.40 | 1,264.63 | 1,467.95 | 1,512.35 | 1,551.08 | 1,744.99 | 1,861.21 |
Columns are period end dates